Myeloma News and Research

RSS

Dovetail Genomics Launches LinkPrep Technology for Enhanced Genetic Variant Discovery

Dovetail Genomics, a leading innovator in genomic solutions, today announces the commercial launch of its LinkPrep™ technology for genetic variant detection at American Society of Human Genetics (ASHG) conference.

4 Nov 2024

CRISPR and Antibodies Offer New Hope for Improving CAR-T Cell Therapy Outcomes

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

13 Sep 2024

Exploring Retrotransposon-Derived DNA Zip Codes in Myeloma Cell Internalization

A new editorial was published in Oncoscience (Volume 11) on July 13, 2024, entitled, "Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization."

12 Aug 2024

Study Shows the Ability of Protein 'Signatures' to Predict Onset of 67 Diseases

Research on thousands of proteins measured from a drop of blood demonstrates the ability of proteins to predict the onset of many diverse diseases.

24 Jul 2024

Enhancing Drug Discovery Through Automated Protein Labeling

Exact protein observation in cells is crucial for many scientific fields, but it has proven to be a difficult technical task, particularly in living cells where each protein needs to have its fluorescent label applied separately.

22 Apr 2024

Scientists Discover New Class of Molecular Glue Degraders for Cancer Therapy

Cells contain molecular machinery that targets and disposes of unwanted proteins to maintain homeostasis.

17 Nov 2023

New Insights Into Tumor-Immune Interactions Could Lead to More Effective Therapies for Multiple Myeloma

A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.

10 Nov 2023

Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification

Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification.

28 Aug 2023

Scientists Uncover New Mechanism for Degrading Short-Lived Proteins

Short-lived proteins control gene expression in cells to carry out a number of vital tasks, from helping the brain form connections to helping the body mount an immune defense. These proteins are made in the nucleus and are quickly destroyed once they've done their job.

25 Aug 2023

High-Throughput Screening of Existing Drugs to Fight Multiple Myeloma More Effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells.

28 Apr 2023

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Microorganisms live in or on almost every part of the human body and play an important role in the regulation of normal human processes. As a result, changes in the number or type of microorganisms, also known as the microbiome, can contribute to disease and altered responses to therapy, including cancer treatment.

14 Mar 2023

Whole genome sequencing might help better assess tumor evolution

To develop the most efficacious, personalized treatment plans for patients with Hodgkin lymphoma or other cancers, researchers and clinicians must first understand the genetic changes that cause cancer to develop.

23 Feb 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

31 Jan 2023

Researchers find immune-effective ways to destroy cancer cells

Treatment with chimeric antigen receptor T cells (CAR T cells) is often the last hope for patients with lymphoma, multiple myeloma, or certain kinds of leukemia.

26 Jul 2022

Researchers discover a new interferon-gamma receptor signaling pathway

The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).

10 Jun 2022

Study shows new potential target for CAR T cells to inhibit solid tumors

CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.

10 May 2022

Yale researchers find a way to 'supercharge' tumor-attacking T cells

Yale scientists have identified a way to "supercharge" tumor-attacking T cells, a finding that may not only improve the effectiveness of a promising type of cell-based cancer immunotherapy but also expand the number of cancers it can treat.

11 Mar 2022

Leukemia-on-a-chip; The Future of Preventing Therapy Resistance?

We speak to Dr. Chao Ma, one of the speakers at SLAS 2022, about his groundbreaking 'leukemia-on-a-chip' technology and its future within therapy resistance.

From Society for Laboratory Automation and Screening (SLAS) 27 Jan 2022

High-risk lymphoma patients may receive durable benefit from axi-cel CAR T cell therapy

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.

13 Dec 2021